Jane Street Group LLC raised its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 133.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 305,652 shares of the company's stock after buying an additional 174,797 shares during the period. Jane Street Group LLC owned approximately 0.21% of MiMedx Group worth $1,806,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Harbor Capital Advisors Inc. increased its stake in shares of MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company's stock valued at $6,074,000 after acquiring an additional 770,744 shares during the period. Millennium Management LLC boosted its stake in MiMedx Group by 339.9% during the 2nd quarter. Millennium Management LLC now owns 889,446 shares of the company's stock valued at $6,164,000 after purchasing an additional 687,267 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of MiMedx Group by 47.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company's stock valued at $8,958,000 after purchasing an additional 413,443 shares during the period. Paradigm Capital Management Inc. NY raised its stake in shares of MiMedx Group by 6.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company's stock worth $28,879,000 after buying an additional 258,700 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of MiMedx Group in the second quarter valued at $988,000. 79.15% of the stock is currently owned by institutional investors.
Separately, StockNews.com lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $12.00.
View Our Latest Report on MDXG
Shares of MiMedx Group stock opened at $9.13 on Thursday. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The firm has a market capitalization of $1.34 billion, a PE ratio of 16.60 and a beta of 1.97. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The stock's fifty day moving average is $8.21 and its 200-day moving average is $7.13.
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.